Company: PCRX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001104659-25-041219
Chunk: 61

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 61
---
, Ms. Riker had an existing executive employment agreement. Ms. Riker’s annual base salary was $374,700 per year, which was not adjusted in connection with her appointment as interim Chief Financial Officer. Ms. Riker participated in the Company’s annual cash incentive bonus program for executive officers, with her annual incentive target set at 50% of her annual base salary, which was not adjusted in connection with her appointment as interim Chief Financial Officer. Ms. Riker also a participated in the Company’s cash LTIP, and her incentive target for such program was also not adjusted in connection with her appointment as interim Chief Financial Officer. In connection with her appointment as interim Chief Financial Officer, Ms. Riker received a $75,000 bonus which is repayable to the Company in the event that, within one year of payment, Ms. Riker’s employment is terminated for “cause” or she resigns for any reason other than “good reason” (each term as defined in her executive employment agreement). Ms. Riker participates in the Company’s other benefit programs generally available to employees of the Company. Retention Equity Grants to Kristen Williams and Daryl Gaugler In February 2024, in recognition of the fact that there was a need to retain critical executive talent with the appointment of a new CEO and in recognition of a heightened workload associated with the transition to a new CEO leading up to and after his appointment, the People & Compensation Committee awarded a retention equity grant to each of Kristen Williams, Chief Administrative Officer and Secretary, and Daryl Gaugler, at the time the Company’s Chief Operating Officer. Each of Ms. Williams and Mr. Gaugler received an RSU grant of 33,700 shares of the Company’s common stock that have a two-year cliff-vest occurring on February 1, 2026. In making these retention grants, the People & Compensation Committee considered competitive market data for life sciences companies with a similar fact pattern as well as the criticality of Ms. Williams and Mr. Gaugler to the Company and the need to retain their leadership during a period of transition. Jonathan Slonin Promotion to Chief Medical Officer In December 2023, Jonathan Slonin was promoted to Chief Medical Officer. Dr. Slonin received 10,000 stock options and 5,000 RSUs for his promotion to Chief Medical Officer. In the case of promotional grants, the Company’s practice is to grant such awards in the month following the promotion, which, in Dr. Sl